Effects of peptide therapy on ex vivo T-cell responses

Journal of Allergy and Clinical Immunology

Volumn 101, Issue 4 I, 1998, Pages 506-513

  Marcotte, Gregory V ^a   Braun, Christine M ^a   Norman, Philip S ^a   Nicodemus, Christopher F ^b   Kagey Sobotka, Anne ^a   Lichtenstein, Lawrence M ^a   Essayan, David M ^a,c  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b ImmuLogic Pharmaceutical Corporation   (United States)

^c JOHNS HOPKINS ASTHMA AND ALLERGY CENTER   (United States)

Author keywords

Allergen; IL 4; Immunotherapy; Peptide; T cell

Indexed keywords

ALLERVAX CAT; EPITOPE; INTERFERON; INTERLEUKIN 4; PEPTIDE; UNCLASSIFIED DRUG;

ANTIGEN ANTIBODY COMPLEX; ANTIGEN PRESENTING CELL; ANTIGEN SPECIFICITY; ARTICLE; CELL PROLIFERATION; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNOLOGICAL TOLERANCE; PHENOTYPE; PRIORITY JOURNAL;

EID: 0031959521     PISSN: 00916749     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0091-6749(98)70358-6     Document Type: Article

References (34)

1. Noon L, Cantab BO. Prophylactic inoculation against hay fever. Lancet 1911;1:1572-3.
2. Frankland AW, Augustin R. Prophylaxis of summer hay-fever and asthma. Lancet 1954;1:1055-7.
3. Van Metre TE, Adkinson NF, Amodio FJ, Kagey-Sobotka A, Lichtenstein LM, Mardiney MR Jr, et al. A comparison of immunotherapy schedules for injection treatment of ragweed pollen hay fever. J Allergy Clin Immunol 1982;69:181-93.
4. Creticos PS, Van Metre TE, Mardiney MR, Rosenberg GL, Norman PS, Adkinson NF. Dose response of IgE and IgG antibodies during ragweed immunotherapy. J Allergy Clin Immunol 1984;73:94-104.
5. Meriney DK, Kothari HY, Chinoy P, Chinoy P, Grieco MH. The clinical and immunologic efficacy of immunotherapy with modified ragweed extract (allergoid) for ragweed hay fever. Ann Allergy 1986;56:34-8.
6. Bosquet J, Maasch H, Martinot B, Hejjaoui A, Wahl R, Michel FB. Double-blind, placebo-controlled immunotherapy with mixed grass-pollen allergoids. J Allergy Clin Immunol 1988;82:439-46.
7. Rocktin RE, Sheffer AL, Greineder DK, Melmon KL. Generation of antigen-specific suppressor cells during allergy desensitization. N Engl J Med 1980;302:1213-9.
8. Varney VA, Hamid QA, Gaga M, Ying S, Jacobson M, Frew AJ, et al. Influence of grass pollen immunotherapy on cellular infiltration and cytokine mRNA expression during allergen-induced late-phase cutaneous responses. J Clin Invest 1993;92:644-51.
9. Greenstein JL, Morgenstern JP, LaRaia J, Counsell CM, Goodwin WH, Lussier A, et al. Ragweed immunotherapy decreases T cell reactivity to recombinant Amb a 1 [abstract]. J Allergy Clin Immunol 1992;89:322.
10. Secrist H, Chelen C, Wen Y, Marshall JD, Umetsu DT. Allergen immunotherapy decreases interleukin 4 production in CD4+ T cells from allergic individuals. J Exp Med 1993;178:2123-30.
11. Jutel M, Pichler WJ, Skrbic D, Urwyler A, Dahinden C, Muller UR. Bee venom immunotherapy results in decrease of IL-4 and IL-5 and increase of IFN-gamma secretion in specific allergen-stimulated T cell cultures. J Immunol 1995;154:4187-94.
12. Varney VA, Hamid QA, Gaga M, Ying S, Jacobson M, Frew AJ, et al. Influence of grass pollen immunotherapy on cellular infiltration and cytokine mRNA expression during allergen-induced late-phase cutaneous responses. J Clin Invest 1993;92:644-51.
13. McHugh SM, Deighton J, Stewart AG, Lachmann PJ, Ewan PW. Bee venom immunotherapy induces a shift in cytokine responses from a TH-2 to TH-1 dominant pattern: comparison of rush and conventional immunotherapy. Clin Exp Allergy 1995;25:828-38.
14. Lack G, Nelson HS, Amran D, Oshiba A, Jung T, Bradley KL, et al. Rush immunotherapy results in allergen-specific alterations in lymphocyte function and interferon-γ, production in CD4+ T cells. J Allergy Clin Immunol 1997;99:503-8.
15. Hamid Q, Azzawi M, Ying S, Moqbel R, Wardlaw AJ, Corrigan CJ, et al. Expression of mRNA for interleukin-5 in mucosal bronchial biopsies from asthma. J Clin Invest 1991;87:1541-6.
16. Robinson D, Hamid Q, Ying S, Tsicopoulos A, Barkans J, Bentley AM, et al. Predominant Th2-like bronchoalveolar T-lymphocyte population in atopic asthma. N Engl J Med 1992;326:298-304.
17. Ying S, Durham SR, Corrigan CJ, Hamid Q, Kay AB. Phenotype of cells expressing mRNA for Th2-type (interleukin 4 and 5) and Th1-type (interleukin 2 and interferon gamma) cytokines in bronchoalveolar lavage and bronchial biopsies from atopic asthmatic and normal control subjects. Am J Respir Cell Mol Biol 1995;12:477-87.
18. Bently AM, Meng Q, Robinson DS, Hamid Q, Kay AB, Durham SR. Increases in activated T lymphocytes, eosinophils, and cytokine mRNA expression for interleukin-5 and granulocyte/macrophage colony stimulating factor in bronchial biopsies after allergen inhalation challenge in atopic asthmatics. Am J Respir Cell Mol Biol 1993;8:35-42.
19. Robinson D, Hamid Q, Bently A, Ying S, Kay AB, Durham SR. Activation of CD4+ T cells, increased Th2-type cytokine mRNA expression, and eosinophil recruitment in bronchoalveolar lavage after allergen challenge in patients with atopic asthma. J Allergy Clin Immunol 1993;92:313-24.
20. Huang S-K, Xiao H, Kleine-Tebbe J, Paciotti G, Marsh DG, Lichtenstein LM, et al. IL-13 expression at the sites of allergen challenge in patients with asthma. J Immunol 1995;155:2688-94.
21. Robinson DS, Ying S, Bently AM, Meng Q, North J, Durham SR, et al. Relationships among numbers of bronchoalveolar lavage cells expressing messenger ribonucleic acid for cytokines, asthma symptoms, and airway methacholine responsiveness in atopic asthma. J Allergy Clin Immunol 1993;92:397-403.
22. Borish L, Rosenwasser LJ. Update on cytokines. J Allergy Clin Immunol 1996;97:719-33.
23. Norman PS. Modern concepts of immunotherapy. Curr Opin Immunol 1993;5:968-73.
24. Briner TJ, Kuo M-C, Keating KM, Rogers BL, Greenstein JL. Peripheral T-cell tolerance induced in naive and primed mice by subcutaneous injection of peptides from the major cat allergen Fel d 1. Proc Natl Acad Sci USA 1993;90:7608-12.
25. Fasler S, Aversa G, Terr A, Thestrup-Pederson K, de Vries JE, Yssel H. Peptide-induced anergy in allergen-specific human Th2 cells results in lack of cytokine production and B cell help for IgE synthesis. J Immunol 1995;155:4199-206.
26. Simons FER, Imada M, Li Y, Watson WTA, HayGlass KT. Fel d 1 peptides: effect on skin tests and cytokine synthesis in cat-allergic human subjects. Internatl Immunol 1996;8:1937-45.
27. Norman PS, Ohman JL Jr, Long AA, Creticos PS, Gefter MA, Suaked Z, et al. Treatment of cat allergy with T-cell reactive peptides. Am J Respir Crit Care Med 1996;154:1623-8.
28. Norman PS, Nicodemus CF, and the ALLERVAX Cat Study Group. Multicenter study of several doses of ALLER-VAX cat peptides in the treatment of cat allergy [abstract]. J Allergy Clin Immunol 1997;99:127.
29. Essayan DM, Huang SK, Kagey-Sobotka A, Lichtenstein LM. Differential efficacy of lymphocyte- and monocyte-selective pretreatment with a type 4 cyclic nucleotide phosphodiesterase inhibitor on antigen-driven proliferation and cytokine gene expression in human peripheral blood mononuclear cells. J Allergy Clin Immunol 1997; 99:28-37.
30. Morgenstern JP, Griffith IJ, Brauer AW, Rogers BL, Bond JF, Chapman MD, et al. Determination of the amino acid sequence of Fel d 1, the major allergen of the domestic cat: protein sequence analysis and cDNA cloning. Proc Natl Acad Sci USA 1991;88:9690-4.
31. Essayan DM, Han W-F, Li X-M. Xiao H-Q, Kleine-Tebbe J, Huang SK. Clonal diversity of interleukin-4 and interleukin-13 expression in human allergen-specific T lymphocytes. J Allergy Clin Immunol 1996;98:1035-44.
32. Essayan DM, Huang SK, Undem BJ, Kagey-Sobotka A, Lichtenstein LM. Modulation of antigen- and mitogen-induced proliferative responses of peripheral blood mononuclear cells by nonselective and isozyme selective cyclic nucleotide phosphodiesterase inhibitors. J Immunol 1994;153:3408-16.
33. Fields PE, Gajewski TF, Fitch FW. Blocked Ras activation in anergic CD4+ T cells. Science 1996;271:1276-8.
34. Smilek DE, Wraith DC, Hodgkinson S, Dwivedy S, Steinman L, McDevitt HO. A single amino acid change in a myelin basic protein peptide confers the capacity to prevent rather than induce experimental autoimmune encephalomyelitis. Immunology 1991;88:9633-7.